Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Rhea-AI Summary

Eledon Pharmaceuticals (Nasdaq: ELDN) will present 24-month follow-up data from eight patients in a Phase 1b long-term extension evaluating tegoprubart in de novo kidney transplant recipients at the American Society of Transplant Surgeons Winter Symposium, January 23–25, 2026.

Key results from the eight-patient cohort: no biopsy-proven acute rejection, no graft loss, no deaths, no new-onset diabetes mellitus, and no de novo donor-specific antibody formation during the study period. Mean eGFR rose from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months. Poster #62 will be presented January 23, 2026; the poster will be posted in the company's Investors section after the presentation.

Positive

• No biopsy-proven acute rejection reported during 24 months
• No graft loss, deaths, new-onset diabetes, or de novo DSA observed
• Mean eGFR increased from 67.0 to 74.2 mL/min/1.73 m² (12→24 months)

Negative

• Very small cohort of only eight patients limits generalizability
• Single-arm Phase 1b design lacks a randomized control group

News Market Reaction – ELDN

-4.04%

1 alert

-4.04% News Effect

-$7M Valuation Impact

$161M Market Cap

0.8x Rel. Volume

On the day this news was published, ELDN declined 4.04%, reflecting a moderate negative market reaction. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $161M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase 1b participants: 8 patients eGFR at 12 months: 67.0 mL/min/1.73 m² eGFR at 24 months: 74.2 mL/min/1.73 m² +2 more

5 metrics

Phase 1b participants 8 patients Long-term extension in kidney transplantation

eGFR at 12 months 67.0 mL/min/1.73 m² Mean eGFR in Phase 1b extension

eGFR at 24 months 74.2 mL/min/1.73 m² Mean eGFR in Phase 1b extension

Follow-up duration 24 months Long-term tegoprubart kidney transplant data

12-month timepoint 12 months Baseline comparison for eGFR change

Market Reality Check

Price: $2.90 Vol: Volume 540,426 is below 2...

low vol

$2.90 Last Close

Volume Volume 540,426 is below 20-day average 844,998 (relative 0.64x), suggesting a modest pre-news reaction. low

Technical Shares trade below 200-day MA, with price 2.23 versus MA 2.7, indicating a longer-term downtrend pre-news.

Peers on Argus

ELDN is up 1.36% on the day, while select biotech peers like CABA and NVCT are a...

2 Up

ELDN is up 1.36% on the day, while select biotech peers like CABA and NVCT are also positive and AARD is negative. Momentum scanner shows only 2 peers (CHRS, CABA) in upside momentum, and backend flags this as not a sector-wide move.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Milestones & outlook	Positive	+0.0%	Outlined 2025 progress, Phase 2 BESTOW data, financing and 2026 tegoprubart plans.
Dec 01	Conference participation	Neutral	-6.1%	Announced CEO fireside chat at major healthcare conference with webcast access.
Nov 18	Islet trial update	Positive	-4.9%	Reported first six type 1 diabetes patients achieving and maintaining insulin independence.
Nov 14	Earnings & financing	Negative	-8.0%	Q3 loss update plus BESTOW data alongside dilutive underwritten public offering.
Nov 12	Equity offering	Negative	-11.3%	Priced ~$50M offering of common stock and pre-funded warrants at set terms.

Pattern Detected

Recent history shows positive clinical and corporate updates often met with flat or negative price reactions, while financings and offerings have aligned with notable downside moves.

Recent Company History

Over the last few months, ELDN has focused on tegoprubart across kidney and islet transplantation, highlighted in the Jan 8, 2026 milestone and outlook update and prior BESTOW Phase 2 data. Conference participation in Dec 2025 and strong islet transplant results in Nov 2025 were followed by weak or negative price reactions. In contrast, the Nov 12–14, 2025 equity offering and related earnings/financing announcements coincided with more pronounced declines. Today’s long-term Phase 1b kidney data fits the ongoing clinical narrative of safety and kidney function preservation.

Market Pulse Summary

This announcement highlights 24-month Phase 1b kidney transplant data for tegoprubart, with mean eGF...

Analysis

This announcement highlights 24-month Phase 1b kidney transplant data for tegoprubart, with mean eGFR improving from 67.0 to 74.2 mL/min/1.73 m² and no reported biopsy-proven rejection or graft loss in 8 patients. It complements prior BESTOW Phase 2 and islet transplant results, reinforcing a consistent safety and kidney function story. Investors may focus on how these long-term outcomes support potential Phase 3 design and future regulatory interactions, alongside the company’s existing financing history and cash runway.

Key Terms

phase 1b, estimated glomerular filtration rate (egfr), biopsy-proven acute rejection, de novo donor-specific antibody, +2 more

6 terms

phase 1b medical

"24-month follow-up data from eight patients enrolled in the Phase 1b trial"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

estimated glomerular filtration rate (egfr) medical

"Mean estimated glomerular filtration rate (eGFR) increased over the measurement period"

Estimated glomerular filtration rate (eGFR) is a test that measures how well your kidneys are filtering waste from your blood. It helps doctors check kidney health and detect problems early, much like how a water filter's effectiveness can be tested by how clean the water becomes.

biopsy-proven acute rejection medical

"There were no episodes of biopsy-proven acute rejection, graft loss, death"

A biopsy-proven acute rejection is when a tissue sample from a transplanted organ shows clear signs that the recipient’s immune system is attacking that organ soon after transplant. For investors, it matters because this objective, lab-confirmed diagnosis is a key measure of how well anti-rejection drugs, medical devices, or transplant procedures are working, and it can directly affect trial outcomes, regulatory decisions, patient survival rates, and market demand for treatments.

de novo donor-specific antibody medical

"no ... de novo donor-specific antibody formation during the study period"

De novo donor-specific antibody (DSA) is an immune protein that develops after an organ transplant that targets markers on the donated organ and was not present before surgery. For investors, these antibodies matter because their appearance is an early warning of immune attack on the graft, often prompting additional treatments, monitoring or interventions that can raise medical costs, affect patient outcomes and influence demand for diagnostics and therapies tied to transplant care.

anti-cd40l antibody medical

"Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen"

An anti-CD40L antibody is a laboratory-made protein that binds to CD40 ligand, a molecule that helps turn immune responses on or off, and by doing so it dampens or reprograms parts of the immune system. Investors pay attention because these drugs target diseases like autoimmune conditions or transplant rejection, so clinical trial outcomes, safety signals, and regulatory decisions can sharply affect a developer’s market value, similar to how a promising new engine can change an automaker’s prospects.

immunosuppression regimen medical

"Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen"

An immunosuppression regimen is a planned combination of medications and dosing schedules used to reduce a patient’s immune response, most often to prevent rejection of a transplanted organ or to control autoimmune disease. Think of it as a tailored recipe or safety checklist that balances preventing the immune system from attacking healthy tissue while minimizing side effects. For investors, the regimen matters because it shapes drug demand, treatment costs, clinical trial outcomes, and regulatory approval decisions for therapies in this market.

AI-generated analysis. Not financial advice.

Data from eight participants continue to support safety and tolerability profile of tegoprubart

Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months

IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona.

There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months.

Details on the poster presentation are below:

Title: Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen
Poster: #62
Session Title: Poster Session B
Date: Friday, January 23, 2026, from 5:45 - 7:15 p.m. PT

Following the presentation, a copy of the poster will be available in the Investors section of the Company’s website at https://ir.eledon.com/news-and-events/publications-and-presentations.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to establish and maintain proper and effective internal control over financial reporting and other risks disclosed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 14, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

What 24-month results did ELDN present for tegoprubart in kidney transplant patients on January 23, 2026?

Eledon presented 24-month follow-up from eight patients showing no biopsy-proven acute rejection, no graft loss or deaths, no new-onset diabetes, no de novo donor-specific antibodies, and mean eGFR rising from 67.0 to 74.2 mL/min/1.73 m².

How many patients were included in ELDN's tegoprubart Phase 1b long-term extension?

The presented dataset comprises eight patients followed to 24 months.

When and where will Eledon present the tegoprubart poster for ELDN?

Poster #62 will be presented at the American Society of Transplant Surgeons Winter Symposium on January 23, 2026, during Poster Session B from 5:45–7:15 p.m. PT.

Will the tegoprubart poster from ELDN be available after the conference?

Yes. A copy of the poster will be posted in the Investors section of the company's website after the presentation.

What are the main limitations of ELDN's reported tegoprubart 24-month data?

The dataset is from a small, single-arm Phase 1b cohort of eight patients, limiting statistical power and generalizability.